Overview
This GLP-2 R-class compound represents the next step in multi-receptor incretin pharmacology: a synthetic triple agonist engaging GLP-1, GIP, and glucagon receptor pathways simultaneously. Note for study design: the 'GLP-3' retail designation is unrelated to the endogenous GLP-3 peptide produced by proglucagon processing — this compound is a synthetic triple receptor agonist with a distinct pharmacology.
Mechanism of Action
At GLP-1R, the compound activates Gs-coupled cAMP signaling in beta-cell preparations, contributing to glucose-dependent insulin secretion and glucagonostatic activity. At GIPR it mimics native GIP signaling, driving complementary insulinotropic responses and adipokine modulation in adipocyte preparations. The distinguishing third arm is glucagon receptor engagement: in hepatic and adipose preparations, GCGR activation is associated with cAMP-driven energy expenditure signaling, fatty acid oxidation pathway activity, and thermogenic marker upregulation — layered alongside the incretin pathways in a multi-receptor crosstalk profile unique among metabolic tool compounds.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder
- CAS Number: 2381089-83-2
- Molecular Weight: ~4731 g/mol
- Chemical Formula: C₂₂₁H₃₄₂N₄₆O₆₈
- Synonyms: GLP-2 R-class, LY3437943, triple incretin agonist
Research Applications
- Triple receptor agonism research
- Incretin pathway crosstalk studies
- Energy expenditure and thermogenic signaling
- Hepatic glucose output regulation models
- Adipokine and lipid metabolism research
- Multi-receptor agonist modeling
